Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 38(30): 5873-5889, 2019 07.
Article in English | MEDLINE | ID: mdl-31253871

ABSTRACT

Cutaneous melanoma is one of the most aggressive cancers characterized by a high plasticity, a propensity for metastasis, and drug resistance. Melanomas are composed of phenotypically diverse subpopulations of tumor cells with heterogeneous molecular profiles that reflect intrinsic invasive abilities. In an attempt to identify novel factors of the melanoma invasive cell state, we previously investigated the nature of the invasive secretome by using a comparative proteomic approach. Here, we have extended this analysis to show that PTX3, an acute phase inflammatory glycoprotein, is one such factor secreted by invasive melanoma to promote tumor cell invasiveness. Elevated PTX3 production was observed in the population of MITFlow invasive cells but not in the population of MITFhigh differentiated melanoma cells. Consistently, MITF knockdown increased PTX3 expression in MITFhigh proliferative and poorly invasive cells. High levels of PTX3 were found in tissues and blood of metastatic melanoma patients, and in BRAF inhibitor-resistant melanoma cells displaying a mesenchymal invasive MITFlow phenotype. Genetic silencing of PTX3 in invasive melanoma cells dramatically impaired migration and invasion in vitro and in experimental lung extravasation assay in xenografted mice. In contrast, addition of melanoma-derived or recombinant PTX3, or expression of PTX3 enhanced motility of low migratory cells. Mechanistically, autocrine production of PTX3 by melanoma cells triggered an IKK/NFκB signaling pathway that promotes migration, invasion, and expression of the EMT factor TWIST1. Finally, we found that TLR4 and MYD88 knockdown inhibited PTX3-induced melanoma cell migration, suggesting that PTX3 functions through a TLR4-dependent pathway. Our work reveals that tumor-derived PTX3 contributes to melanoma cell invasion via targetable inflammation-related pathways. In addition to providing new insights into the biology of melanoma invasive behavior, this study underscores the notion that secreted PTX3 represents a potential biomarker and therapeutic target in a subpopulation of MITFlow invasive and/or refractory melanoma.


Subject(s)
C-Reactive Protein/physiology , Melanoma/metabolism , NF-kappa B/metabolism , Neoplasm Metastasis/physiopathology , Serum Amyloid P-Component/physiology , Signal Transduction , Skin Neoplasms/metabolism , Toll-Like Receptor 4/metabolism , Animals , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Heterografts , Humans , Melanoma/pathology , Mice , Neoplasm Invasiveness , Skin Neoplasms/pathology , Up-Regulation , Melanoma, Cutaneous Malignant
2.
J Virol ; 74(9): 3948-52, 2000 May.
Article in English | MEDLINE | ID: mdl-10756006

ABSTRACT

Cytotoxic T lymphocytes (CTLs) play a central role in the control of persistent human cytomegalovirus (HCMV) infection in healthy virus carriers. Previous analyses of the specificity of HCMV-reactive CD8(+) CTLs drawn from in vitro models in which antigen-presenting cells were autologous fibroblasts infected with laboratory HCMV strains have shown focusing of CTL responses against the major tegument protein, pp65. By contrast, the 72-kDa major immediate-early protein (IE1) was identified as a minor target for this response. Here we have studied the fine specificity and T-cell-receptor features of T-cell clones generated against autologous B lymphoblastoid cell lines stably transfected with HCMV cDNA coding for either pp65 or a natural variant of IE1. This strategy allowed efficient generation of T-cell clones against IE1 and pp65 and led to the identification of several new IE1 and pp65 epitopes, including some located in polymorphic regions of IE1. Such an approach may provide relevant information about the characteristics of the CTL response to IE1 and the effect of viral polymorphism on the immune response against HCMV.


Subject(s)
B-Lymphocytes/immunology , Cytomegalovirus/immunology , Immediate-Early Proteins/immunology , Phosphoproteins/immunology , Receptors, Antigen, T-Cell, alpha-beta/immunology , T-Lymphocytes, Cytotoxic/immunology , Viral Matrix Proteins/immunology , Viral Proteins , Alleles , Animals , COS Cells , Cell Line, Transformed , Epitopes, T-Lymphocyte/immunology , HLA-A2 Antigen/immunology , HLA-B Antigens/immunology , HLA-B18 Antigen , Histocompatibility Antigens Class I/immunology , Humans , Immediate-Early Proteins/genetics , Phosphoproteins/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Reverse Transcriptase Polymerase Chain Reaction/methods , T-Lymphocytes, Cytotoxic/cytology , Viral Matrix Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...